High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries
BACKGROUND: We aimed to elucidate which vaccines were accepted by European countries as valid proof of vaccination against COVID-19 for international travelers. METHOD: On 27-September-2021 a cross-sectional study was conducted on VisaGuide.World, that reports on valid vaccines for international tra...
Published in: | Travel Medicine and Infectious Disease |
---|---|
Main Authors: | , , , , |
Format: | Text |
Language: | English |
Published: |
Elsevier Ltd.
2022
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977214/ https://doi.org/10.1016/j.tmaid.2022.102321 |
id |
ftpubmed:oai:pubmedcentral.nih.gov:8977214 |
---|---|
record_format |
openpolar |
spelling |
ftpubmed:oai:pubmedcentral.nih.gov:8977214 2023-05-15T16:50:58+02:00 High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries Dal-Ré, Rafael Banzi, Rita Becker, Sören L. Launay, Odile Pavli, Androula 2022 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977214/ https://doi.org/10.1016/j.tmaid.2022.102321 en eng Elsevier Ltd. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977214/ http://dx.doi.org/10.1016/j.tmaid.2022.102321 © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Travel Med Infect Dis Article Text 2022 ftpubmed https://doi.org/10.1016/j.tmaid.2022.102321 2022-04-10T00:36:42Z BACKGROUND: We aimed to elucidate which vaccines were accepted by European countries as valid proof of vaccination against COVID-19 for international travelers. METHOD: On 27-September-2021 a cross-sectional study was conducted on VisaGuide.World, that reports on valid vaccines for international travelers. Other databases, lay press and regulatory agencies were also checked. The main outcome measure was which of the vaccines included on the WHO emergency use listing (EUL) [ChAdOx1 (Vaxzevria, Covishield),BNT162b2,mRNA-1273,Ad26.CoV2.S,BBIBP-CorV,CoronaVac] and Sputnik V, were accepted in each country. The influence of the vaccines approved for COVID-19 vaccination programs on the vaccines recognized as proof of vaccination was assessed. RESULTS: There was a remarkable heterogeneity on the vaccines accepted as proof of vaccination among 46 countries. Russia accepted only one. Cyprus, Greece and Slovenia accepted all vaccines considered. Eleven countries accepted the seven WHO EUL vaccines: eight EU countries, plus Iceland, Norway and Switzerland. Seven EU countries accepted only the four EMA-authorized vaccines. Considering Covishield as equivalent to Vaxzevria, 69% of countries recognized only vaccinated travelers who received any of the vaccines approved for vaccination programs in the country of arrival as valid. CONCLUSION: Vaccines accepted as proof of vaccination should be harmonized. Accepting any of the WHO EUL vaccines would be a scientifically sound objective. Text Iceland PubMed Central (PMC) Norway Sputnik ENVELOPE(66.167,66.167,-70.833,-70.833) Travel Medicine and Infectious Disease 48 102321 |
institution |
Open Polar |
collection |
PubMed Central (PMC) |
op_collection_id |
ftpubmed |
language |
English |
topic |
Article |
spellingShingle |
Article Dal-Ré, Rafael Banzi, Rita Becker, Sören L. Launay, Odile Pavli, Androula High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries |
topic_facet |
Article |
description |
BACKGROUND: We aimed to elucidate which vaccines were accepted by European countries as valid proof of vaccination against COVID-19 for international travelers. METHOD: On 27-September-2021 a cross-sectional study was conducted on VisaGuide.World, that reports on valid vaccines for international travelers. Other databases, lay press and regulatory agencies were also checked. The main outcome measure was which of the vaccines included on the WHO emergency use listing (EUL) [ChAdOx1 (Vaxzevria, Covishield),BNT162b2,mRNA-1273,Ad26.CoV2.S,BBIBP-CorV,CoronaVac] and Sputnik V, were accepted in each country. The influence of the vaccines approved for COVID-19 vaccination programs on the vaccines recognized as proof of vaccination was assessed. RESULTS: There was a remarkable heterogeneity on the vaccines accepted as proof of vaccination among 46 countries. Russia accepted only one. Cyprus, Greece and Slovenia accepted all vaccines considered. Eleven countries accepted the seven WHO EUL vaccines: eight EU countries, plus Iceland, Norway and Switzerland. Seven EU countries accepted only the four EMA-authorized vaccines. Considering Covishield as equivalent to Vaxzevria, 69% of countries recognized only vaccinated travelers who received any of the vaccines approved for vaccination programs in the country of arrival as valid. CONCLUSION: Vaccines accepted as proof of vaccination should be harmonized. Accepting any of the WHO EUL vaccines would be a scientifically sound objective. |
format |
Text |
author |
Dal-Ré, Rafael Banzi, Rita Becker, Sören L. Launay, Odile Pavli, Androula |
author_facet |
Dal-Ré, Rafael Banzi, Rita Becker, Sören L. Launay, Odile Pavli, Androula |
author_sort |
Dal-Ré, Rafael |
title |
High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries |
title_short |
High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries |
title_full |
High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries |
title_fullStr |
High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries |
title_full_unstemmed |
High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries |
title_sort |
high heterogeneity on the accepted vaccines for covid-19 certificates in european countries |
publisher |
Elsevier Ltd. |
publishDate |
2022 |
url |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977214/ https://doi.org/10.1016/j.tmaid.2022.102321 |
long_lat |
ENVELOPE(66.167,66.167,-70.833,-70.833) |
geographic |
Norway Sputnik |
geographic_facet |
Norway Sputnik |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
Travel Med Infect Dis |
op_relation |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977214/ http://dx.doi.org/10.1016/j.tmaid.2022.102321 |
op_rights |
© 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
op_doi |
https://doi.org/10.1016/j.tmaid.2022.102321 |
container_title |
Travel Medicine and Infectious Disease |
container_volume |
48 |
container_start_page |
102321 |
_version_ |
1766041082065321984 |